ArticleStroke and vascular neurology2026
Outcomes of Onyx embolisation as primary treatment for intracranial dural arteriovenous fistulas over the past two decades.
Article in Stroke and vascular neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost current studies on Onyx are limited by small sample sizes and often involve its use in combination with other embolic materials, with few investigations specifically evaluating Onyx as a sole embolic agent.
methodsUsing the Dural Arteriovenous Fistula Research and Management in China (DREAM-INI) database, we identified patients who underwent primary treatment for dural arteriovenous fistula (DAVF) with Onyx-only embolisation. Data collected included patient demographics, comorbidities, clinical manifestations, DAVF location, arterial supply, Borden and Cognard classifications, endovascular modalities, angiographic results, complications, and both clinical and angiographic follow-up. Multivariate logistic regression analyses were conducted to identify predictors of immediate complete obliteration, complications and poor clinical outcomes.
resultsA total of 471 patients with DAVFs underwent primary embolisation using Onyx. The median duration of clinical follow-up was 35.0 months (IQR 10.0-75.3), while the median angiographic follow-up was 24.0 months (IQR 8.0-63.0). Immediate complete obliteration was achieved in 417 patients (88.5%). Procedure-related complications occurred in 31 cases (6.6%). At the final follow-up, 90.6% of patients demonstrated good clinical outcomes. Borden type III DAVFs were positively associated with immediate complete obliteration, whereas the presence of occipital and pial artery feeders was negatively associated. Tentorial location correlated with a higher risk of complications, and age above 65 years emerged as a significant predictor of poor clinical outcome.
conclusionsIn this large single-centre study based on the DREAM-INI database, we report satisfactory obliteration rates, a low incidence of complications and favourable outcomes following Onyx-based single-agent primary embolisation for single DAVFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.